The Latest Breaking News from Centene

Centene Corporation (NYSE:CNC) has agreed to sell Magellan Rx to Prime Therapeutics LLC and PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners.  Centene expects to receive approximately $2.8 billion in aggregate proceeds from the transactions. Magellan Rx is a comprehensive pharmacy solutions organization with specialty drug management, Medicaid administration, and comprehensive pharmacy…

US stock futures traded higher ahead of the much-awaited interest rate decision from the Federal Reserve. Investors, meanwhile, focused on some notable insider trades.

According to Benzinga Pro, during Q1, Centene (NYSE:CNC) earned $852.00 million, a 43.68% increase from the preceding quarter. Centene also posted a total of $37.19 billion in sales, a 14.18% increase since Q4.

Centene Corporation (NYSE:CNC) has reported a Q1 FY22 adjusted EPS of $1.83, compared to $1.63 a year ago, beating the consensus estimate of $1.68. Sales increased 24% Y/Y to $37.18 billion, beating the consensus of $34.50 billion. Health Benefits Ratio of 87.3%, up from 86.8% a year ago, due to a return…